Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Earnings Data
Report Date
Feb 11, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.88Last Year’s EPS
-0.32Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials for obesity treatments, with positive Phase II results and the initiation of Phase III trials. However, the financial report showed increased losses and decreased cash reserves.Company Guidance
Positive Phase II Results for VK2735
The Phase II VENTURE-Oral Dosing Trial successfully achieved its primary and secondary endpoints with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. Up to 97% of subjects achieved at least 5% weight loss.
Initiation of Phase III VANQUISH Registration Program
Viking initiated the Phase III VANQUISH Registration program, including trials in patients with obesity and patients with obesity and type 2 diabetes. Enrollment for these trials is proceeding well and is ahead of schedule.
Strong Financial Position
Viking holds cash, cash equivalents, and short-term investments of $715 million as of the end of the third quarter, which allows the company to complete its planned Phase III obesity trials for VK2735.
VKTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VKTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 22, 2025 | $31.42 | ― | ― |
Jul 24, 2025 | $33.50 | $34.42 | +2.75% |
Apr 23, 2025 | $25.79 | $25.66 | -0.50% |
Feb 05, 2025 | $33.50 | $31.46 | -6.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Viking Therapeutics (VKTX) report earnings?
Viking Therapeutics (VKTX) is schdueled to report earning on Feb 11, 2026, After Close (Confirmed).
What is Viking Therapeutics (VKTX) earnings time?
Viking Therapeutics (VKTX) earnings time is at Feb 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VKTX EPS forecast?
VKTX EPS forecast for the fiscal quarter 2025 (Q4) is -0.88.